VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
08. September 2021 07:15 ET
|
VectivBio AG
BASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Announces Results of Extraordinary General Meeting
03. September 2021 07:15 ET
|
VectivBio AG
BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio to Acquire Comet Therapeutics and Host R&D Day
31. August 2021 07:00 ET
|
VectivBio AG
- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -- VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE...
VectivBio Publishes Invitation to the Extraordinary General Meeting
12. August 2021 07:15 ET
|
VectivBio AG
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and...
VectivBio Nominates Paul R. Carter and Murray W. Stewart for Election to its Board of Directors
12. Juli 2021 07:15 ET
|
VectivBio AG
- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on...
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
24. Juni 2021 07:19 ET
|
VectivBio AG
BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development...
VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure
15. Juni 2021 07:15 ET
|
VectivBio AG
Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IFCIC patients represent over half of the total SBS-IF...
VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
25. Mai 2021 07:15 ET
|
VectivBio AG
Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of...
CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering
13. April 2021 21:53 ET
|
VectivBio AG
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence...
VectivBio Announces Pricing of Initial Public Offering
08. April 2021 22:27 ET
|
VectivBio AG
BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery,...